In this meta-analysis, the researchers found that all TNF-α inhibitors were more effective at treating AS than placebo in direct comparisons, but no differences in efficacy or safety were found between individual TNF-α inhibitors in indirect comparisons.
Tumor necrosis factor promoter polymorphisms were stronger predictors of response to etanercept than to infliximab or adalimumab in patients with spondyloarthritis.
Analyses of results from 2 phase 3 clinical trials suggest that adalimumab is efficacious at treating moderate to severe hidradenitis suppurativa
The U.S. Food and Drug Administration has approved adalimumab (Humira®, Abbvie), a potent blocker of tumor necrosis factor alpha, for the treatment of non-infectious intermediate, posterior, and panuveitis
A subset of patients with RA fail to respond to tumor necrsis factor (TNF) inhibitor therapy. This study was conducted to evaluate the efficacy of tocilizumab, abatacept and rituximab in these patients.
